382 related articles for article (PubMed ID: 28330783)
1. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
2. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
4. [Relation between single Nucleotide Polymorphisms of CYP3A5 Gene and MDR1 Gene Loci and Risk of CML Cytogenetic Relapse].
Yang ZY; Zhang YS; Liang CX; Zhou ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1644-1648. PubMed ID: 30501698
[TBL] [Abstract][Full Text] [Related]
5. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
7. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
8. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
9. [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].
He Y; Zao X; Wei X
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):34-41. PubMed ID: 33177018
[TBL] [Abstract][Full Text] [Related]
10. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
11. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
[TBL] [Abstract][Full Text] [Related]
12. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
[TBL] [Abstract][Full Text] [Related]
14. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
15. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
17. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
Cargnin S; Ravegnini G; Soverini S; Angelini S; Terrazzino S
Pharmacol Res; 2018 May; 131():244-254. PubMed ID: 29427770
[TBL] [Abstract][Full Text] [Related]
18. Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
Natarajan H; Kumar L; Bakhshi S; Sharma A; Velpandian T; Kabra M; Gogia A; Ranjan Biswas N; Gupta YK
Leuk Lymphoma; 2019 Feb; 60(2):418-425. PubMed ID: 30124353
[TBL] [Abstract][Full Text] [Related]
19. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Med Oncol; 2015 Aug; 32(8):213. PubMed ID: 26143137
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
